OpZira, Inc. — SEC Form D Filing

OpZira, Inc. filed an SEC Form D on March 31, 2026, reporting $1.07M raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
March 31, 2026
Amount reported
$1.07M
Round stage
Seed
Industry
Healthcare Technology
Website
https://opzira.com/

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Early detection and ongoing monitoring of ocular diseases are essential for optimizing patient outcomes. Delayed detection can lead to worsening conditions and loss of vision.

Solution

OpZira provides innovative technologies that empower clinicians to detect and monitor ocular diseases early, facilitating timely interventions and treatments.

Why now

With the rise in ocular diseases and the availability of effective treatments, there's a critical need for technologies that enable early detection and monitoring.

Verdict

Investors said yes at that moment because they recognized the urgency of addressing ocular diseases, not because they were confident in the differentiation of OpZira’s technology. They were implicitly betting on the growing trend in preventive healthcare and the necessity of early detection methods, while remaining cautious about the limited upside given existing competition and the reliance on traditional technology adoption cycles. This cleared because the problem addressed was critical, not because the solution was uniquely compelling.

Source: SEC EDGAR Form D filing